BioMark Diagnostics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BUX.CN research report →
Companywww.biomarkdiagnostics.com
BioMark Diagnostics Inc. , an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis.
- CEO
- Rashid Ahmed Maula Bux
- IPO
- 2014
- Employees
- 9
- HQ
- Richmond, BC, CA
Price Chart
Valuation
- Market Cap
- $62.00M
- P/E
- -36.48
- P/S
- 675.63
- P/B
- 122.05
- EV/EBITDA
- -48.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -147.92%
- Op Margin
- -2073.23%
- Net Margin
- -1852.06%
- ROE
- -153.00%
- ROIC
- -145.19%
Growth & Income
- Revenue
- $154.22K · -5.52%
- Net Income
- $-1,927,280 · -35.02%
- EPS
- $-0.02 · -35.33%
- Op Income
- $-1,908,137
- FCF YoY
- -11.12%
Performance & Tape
- 52W High
- $0.64
- 52W Low
- $0.27
- 50D MA
- $0.59
- 200D MA
- $0.46
- Beta
- -0.29
- Avg Volume
- 5.42K
Get TickerSpark's AI analysis on BUX.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BUX.CN Coverage
We haven't published any research on BUX.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BUX.CN Report →